Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a ubiquitous neuropeptide in the central and peripheral nervous systems. PACAP is also produced by pancreatic islet cells. PACAP regulates the glucose and energy metabolism at multiple processes in several tissues. At postprandial states, PACAP potentiates both insulin release from pancreatic β-cells and insulin action in adipocytes, contributing to energy storage. At fasting states, PACAP on the one hand promotes feeding behavior by activating neuropeptide Y neurons in the hypothalamic feeding center, arcuate nucleus, and on the other hand stimulates secretion of catecholamine and glucagon and thereby induces lipolysis in adipocytes and glucose output from liver. Thus, PACAP plays an integrative role in the glucose and energy homeostasis. Dysfunction of expression, secretion and/or action of PACAP might be involved in the type 2 diabetes and metabolic syndrome. PACAP receptor subtype-specific agonists and/or antagonists are hopeful therapeutic agents.
Keywords: VPAC2-R-deficient mice, PACAP receptors, Adipocytes, Lipolysis, Catecholamines
Current Pharmaceutical Design
Title: PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential
Volume: 13 Issue: 11
Author(s): Masanori Nakata and Toshihiko Yada
Affiliation:
Keywords: VPAC2-R-deficient mice, PACAP receptors, Adipocytes, Lipolysis, Catecholamines
Abstract: Pituitary adenylate cyclase activating polypeptide (PACAP) is a ubiquitous neuropeptide in the central and peripheral nervous systems. PACAP is also produced by pancreatic islet cells. PACAP regulates the glucose and energy metabolism at multiple processes in several tissues. At postprandial states, PACAP potentiates both insulin release from pancreatic β-cells and insulin action in adipocytes, contributing to energy storage. At fasting states, PACAP on the one hand promotes feeding behavior by activating neuropeptide Y neurons in the hypothalamic feeding center, arcuate nucleus, and on the other hand stimulates secretion of catecholamine and glucagon and thereby induces lipolysis in adipocytes and glucose output from liver. Thus, PACAP plays an integrative role in the glucose and energy homeostasis. Dysfunction of expression, secretion and/or action of PACAP might be involved in the type 2 diabetes and metabolic syndrome. PACAP receptor subtype-specific agonists and/or antagonists are hopeful therapeutic agents.
Export Options
About this article
Cite this article as:
Nakata Masanori and Yada Toshihiko, PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential, Current Pharmaceutical Design 2007; 13 (11) . https://dx.doi.org/10.2174/138161207780618948
DOI https://dx.doi.org/10.2174/138161207780618948 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Synthesis and Biological Activity of 3-(substitutedphenyl)- 6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry The Influence of Gender and Menopausal Status on Hba1c Variation in a Big Data Study of a Saudi Population
Current Diabetes Reviews HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease
Current Vascular Pharmacology Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Major Depressive Disorder and Diabetes: Does Serotonin Bridge the Gap?
Current Diabetes Reviews Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Possible Roles of Reg Family Proteins in Pancreatic Islet Cell Growth
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure - Function Analysis of Peptide Analogs of SQSPA with Respect to α-glucosidase and α-amylase Inhibition
Protein & Peptide Letters Effects of Drugs, Phytoestrogens, Nutrients and Probiotics on Endothelial Dysfunction in the Estrogen-Deficient State
Current Pharmaceutical Design